Provided by Tiger Fintech (Singapore) Pte. Ltd.

Petros Pharmaceuticals Inc

0.0730
-0.0049-6.29%
Post-market: 0.0729-0.0001-0.14%17:07 EDT
Volume:5.33M
Turnover:382.45K
Market Cap:1.84M
PE:-0.02
High:0.0762
Open:0.0750
Low:0.0680
Close:0.0779
Loading ...

Company Profile

Company Name:
Petros Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
21
Office Location:
1185 Avenue of the Americas,Suite 249,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Directors

Name
Position
Joshua N. Silverman
Chairman of the Board
Bruce T. Bernstein
Director
Wayne R. Walker
Director

Shareholders

Name
Position
Fady Boctor
President and Chief Commercial Officer
Mitchell Arnold
Vice President of Finance and Chief Accounting Officer